The Discovery of GLP-1 The story of GLP-1 began in the 1980s, a decade marked by significant advancements in biomedical research
Morales-Barrera R, Rodriguez CS, and Gonzalez M, et al (2019) Impact of immune-related adverse events on survival in patients with metastastic urothelial carcinoma treated with immune-checkpoint inhibitors J Clin Oncol 37 (15_suppl) 4531 86
Issues, such as a small patient population and unique targets, often result in a lack of attention from pharmaceutical companies
Participants received once-daily subcutaneous semaglutide at doses of 0.1 mg (80 patients), 0.2 mg (78 patients), 0.4 mg (82 patients), or placebo (80 patients)
While caffeine doesnt directly cause sleep paralysis, it can cause insomnia which is associated with sleep paralysis
Kalhan SC, Hanson RW